XNCR
Xencor, Inc.16.55
-0.24-1.43%
Dec 16, 4:00:00 PM EST
Earnings Call Transcripts
This Quarter (Q4 '25)
No earnings call transcript available yet
Last Quarter (Q3 '25)
No earnings call transcript available
Key Stats
Market Cap
1.18BP/E (TTM)
-Basic EPS (TTM)
-1.73Dividend Yield
0%Recent Filings
8-K
XmAb819 Phase 1 data released
Xencor unveiled initial Phase 1 data for XmAb819, its ENPP3 x CD3 T-cell engager, showing a 25% overall response rate and 70% disease control rate in 20 heavily pretreated advanced ccRCC patients at target doses. The drug proved well-tolerated, with mostly low-grade CRS and rash during priming, and no ICANS cases. Enrollment in the first dose-expansion cohort has begun. Dose escalation continues.
8-K
Xencor Q2 revenue surges
Xencor reported Q2 2025 revenue of $43.6 million, up from $23.9 million last year, fueled by a $25 million Incyte milestone from Monjuvi's FDA approval in follicular lymphoma. R&D expenses held steady at $61.7 million amid advancing four XmAb candidates in oncology and autoimmune trials, including the new Phase 2b XENITH-UC for ulcerative colitis. Cash stands at $663.8 million, funding operations into 2028. Progress accelerates, yet clinical risks loom.
10-Q
Q2 FY2025 results
Xencor posted Q2 revenue of $43.6M, up 82% y/y from $23.9M, fueled by a $25M milestone from Incyte's tafasitamab approval and steady royalties from Alexion's Ultomiris, while YTD revenue climbed 91% to $76.3M; operating loss narrowed to $33.2M from $55.4M y/y as R&D held flat at $61.7M despite pipeline advances in oncology and autoimmune programs, yet net loss widened to $30.8M from $67.3M due to $8.2M interest expense on royalty liabilities outpacing $7.2M interest income and a $5.0M equity gain. Diluted EPS improved to $(0.41) from $(1.09) on 74.3M shares, reconciling cleanly with no anti-dilution. Cash and marketable debt securities stood at $663.8M, with operating cash burn easing to $52.6M YTD versus $124.2M last year; free cash flow not disclosed in the 10-Q. Gale merger closed April 2025 with no goodwill or intangibles recognized under common control. Patent litigation with Merus drags on, risking IP defenses.
8-K
Xencor adds biotech veteran to board
Xencor appointed Raymond J. Deshaies, Ph.D., to its board on July 31, 2025, adding expertise from his Amgen role overseeing research and nominating over 50 clinical candidates. The move bolsters Xencor's pipeline advancement in engineered antibodies for cancer and autoimmune diseases. Dr. Deshaies receives a $550,000 stock option grant vesting over three years, plus a $50,000 annual retainer. His insights sharpen drug development, yet risks shadow clinical progress.
8-K
Xencor annual meeting results
Xencor, Inc. held its 2025 Annual Meeting on June 12, with 94.68% of shares represented. Stockholders elected all eight director nominees, ratified KPMG LLP as auditors for 2025, and approved adding 3 million shares to the 2023 Equity Incentive Plan despite 23% opposition. They also backed executive compensation on an advisory basis. Board continuity supports steady governance amid biotech volatility.
MGNX
MacroGenics, Inc.
1.35-0.02
MNPR
Monopar Therapeutics Inc.
71.47-3.65
OTLC
Oncotelic Therapeutics, Inc.
0.09+0.00
REGN
Regeneron Pharmaceuticals, Inc.
746.36-6.26
SNSE
Sensei Biotherapeutics, Inc.
8.08+0.19
VINC
Vincerx Pharma, Inc.
0.01+0.00
XBIO
Xenetic Biosciences, Inc.
2.07-0.27
XBIT
XBiotech Inc.
2.45-0.08
XERS
Xeris Biopharma Holdings, Inc.
7.10+0.05
XFOR
X4 Pharmaceuticals, Inc.
3.71-0.05